Cite
HARVARD Citation
Kutsch, N. et al. (2022). Efficacy and Safety of Tirabrutinib and Idelalisib With or Without Obinutuzumab in Relapsed Chronic Lymphocytic Leukemia. HemaSphere. 6 (6), pp. e729-. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Kutsch, N. et al. (2022). Efficacy and Safety of Tirabrutinib and Idelalisib With or Without Obinutuzumab in Relapsed Chronic Lymphocytic Leukemia. HemaSphere. 6 (6), pp. e729-. [Online].